The post President Trump Launches TrumpRx, Promising Lower Drug Prices: Is It Legit? appeared on BitcoinEthereumNews.com.

In brief TrumpRx.gov aggregates steep cash-pay discounts on more than 40 branded drugs, routing users to manufacturers or pharmacies without insurance or accounts. GLP-1 drugs like Ozempic, Wegovy, and Zepbound anchor the launch, with prices cut by as much as 85–93% from U.S. list prices under a most-favored-nation framework. Supporters hail the platform as a breakthrough on affordability, while critics argue it benefits a narrow slice of patients and sidesteps deeper reforms to insurance and drug pricing. TrumpRx.gov, a government-backed platform aimed at slashing U.S. prescription drug prices by tying them to the lowest rates paid in other developed countries, launched late Thursday. The site, branded as a “most-favored-nation” pricing tool, is positioned as a clearinghouse to help users find the best pricing for prescription drugs. Users can search for medications, see sharply discounted cash prices, generate printable or digital coupons, and are then routed to participating manufacturers or pharmacies to complete purchases. No insurance is required, and no account is needed. The White House has billed TrumpRx as a transparency play designed to bypass middlemen—pharmacy benefit managers, insurers, and opaque rebate structures that have long distorted U.S. drug pricing. At launch, the platform lists more than 40 branded drugs from major pharmaceutical companies, including Eli Lilly, Novo Nordisk, Pfizer, and AstraZeneca, with additional medications promised in the coming months.  The rollout focused heavily on GLP-1 agonists, the blockbuster drugs used to treat diabetes and obesity that have become a flashpoint in the broader healthcare affordability debate. Monthly list prices for these drugs often exceed $1,000 in the U.S., far higher than prices in Europe or Asia. Via the TrumpRx portal, those numbers drop sharply for cash-paying users, based on coupons offered by pharma companies: Ozempic (semaglutide for diabetes) is listed as low as $199 per month, down from…

---

Filed under: News - @ February 6, 2026 8:28 pm